Global Gene Modifying Immunotherapy for Blood Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 Gene Modifying Immunotherapy for Blood Cancer Market Overview

• 1.1 Product Overview and Scope of Gene Modifying Immunotherapy for Blood Cancer
• 1.2 Classification of Gene Modifying Immunotherapy for Blood Cancer by Types
  • 1.2.1 Global Gene Modifying Immunotherapy for Blood Cancer Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Types in 2018
  • 1.2.3 CAR T-cell Therapy
  • 1.2.4 TCR T-cell Therapy
• 1.3 Global Gene Modifying Immunotherapy for Blood Cancer Market by Application
  • 1.3.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Acute Lymphocytic Leukemia
  • 1.3.3 Chronic Lymphocytic Leukemia
  • 1.3.4 B Cell Lymphoma
  • 1.3.5 Multiple Myeloma
  • 1.3.6 Other
• 1.4 Global Gene Modifying Immunotherapy for Blood Cancer Market by Regions
  • 1.4.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) Gene Modifying Immunotherapy for Blood Cancer Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Gene Modifying Immunotherapy for Blood Cancer Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Gene Modifying Immunotherapy for Blood Cancer Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Gene Modifying Immunotherapy for Blood Cancer Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Gene Modifying Immunotherapy for Blood Cancer Status and Prospect (2014-2024)
• 1.5 Global Market Size of Gene Modifying Immunotherapy for Blood Cancer (2014-2024)

2 Company Profiles

• 2.1 Novartis
  • 2.1.1 Business Overview
  • 2.1.2 Gene Modifying Immunotherapy for Blood Cancer Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Novartis Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 Bellicum Pharmaceuticals
  • 2.2.1 Business Overview
  • 2.2.2 Gene Modifying Immunotherapy for Blood Cancer Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 Cellectis
  • 2.3.1 Business Overview
  • 2.3.2 Gene Modifying Immunotherapy for Blood Cancer Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 Cellectis Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 Kite Pharma
  • 2.4.1 Business Overview
  • 2.4.2 Gene Modifying Immunotherapy for Blood Cancer Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 Bluebird Bio
  • 2.5.1 Business Overview
  • 2.5.2 Gene Modifying Immunotherapy for Blood Cancer Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 Juno Therapeutics
  • 2.6.1 Business Overview
  • 2.6.2 Gene Modifying Immunotherapy for Blood Cancer Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 Celyad
  • 2.7.1 Business Overview
  • 2.7.2 Gene Modifying Immunotherapy for Blood Cancer Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 Celyad Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 Ziopharm Oncology
  • 2.8.1 Business Overview
  • 2.8.2 Gene Modifying Immunotherapy for Blood Cancer Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 Mustang Bio
  • 2.9.1 Business Overview
  • 2.9.2 Gene Modifying Immunotherapy for Blood Cancer Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Revenue, Gross Margin and Market Share (2017-2018)

3 Global Gene Modifying Immunotherapy for Blood Cancer Market Competition, by Players

• 3.1 Global Gene Modifying Immunotherapy for Blood Cancer Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Gene Modifying Immunotherapy for Blood Cancer Players Market Share
  • 3.2.2 Top 10 Gene Modifying Immunotherapy for Blood Cancer Players Market Share
• 3.3 Market Competition Trend

4 Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Regions

• 4.1 Global Gene Modifying Immunotherapy for Blood Cancer Revenue and Market Share by Regions
• 4.2 North America Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 4.3 Europe Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 4.5 South America Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)

5 North America Gene Modifying Immunotherapy for Blood Cancer Revenue by Countries

• 5.1 North America Gene Modifying Immunotherapy for Blood Cancer Revenue by Countries (2014-2019)
• 5.2 USA Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 5.3 Canada Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 5.4 Mexico Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)

6 Europe Gene Modifying Immunotherapy for Blood Cancer Revenue by Countries

• 6.1 Europe Gene Modifying Immunotherapy for Blood Cancer Revenue by Countries (2014-2019)
• 6.2 Germany Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 6.3 UK Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 6.4 France Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 6.5 Russia Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 6.6 Italy Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Revenue by Countries

• 7.1 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Revenue by Countries (2014-2019)
• 7.2 China Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 7.3 Japan Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 7.4 Korea Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 7.5 India Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)

8 South America Gene Modifying Immunotherapy for Blood Cancer Revenue by Countries

• 8.1 South America Gene Modifying Immunotherapy for Blood Cancer Revenue by Countries (2014-2019)
• 8.2 Brazil Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 8.3 Argentina Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 8.4 Colombia Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Gene Modifying Immunotherapy for Blood Cancer by Countries

• 9.1 Middle East and Africa Gene Modifying Immunotherapy for Blood Cancer Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 9.3 UAE Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 9.4 Egypt Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)
• 9.6 South Africa Gene Modifying Immunotherapy for Blood Cancer Revenue and Growth Rate (2014-2019)

10 Global Gene Modifying Immunotherapy for Blood Cancer Market Segment by Type

• 10.1 Global Gene Modifying Immunotherapy for Blood Cancer Revenue and Market Share by Type (2014-2019)
• 10.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Forecast by Type (2019-2024)
• 10.3 CAR T-cell Therapy Revenue Growth Rate (2014-2024)
• 10.4 TCR T-cell Therapy Revenue Growth Rate (2014-2024)

11 Global Gene Modifying Immunotherapy for Blood Cancer Market Segment by Application

• 11.1 Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share by Application (2014-2019)
• 11.2 Gene Modifying Immunotherapy for Blood Cancer Market Forecast by Application (2019-2024)
• 11.3 Acute Lymphocytic Leukemia Revenue Growth (2014-2019)
• 11.4 Chronic Lymphocytic Leukemia Revenue Growth (2014-2019)
• 11.5 B Cell Lymphoma Revenue Growth (2014-2019)
• 11.6 Multiple Myeloma Revenue Growth (2014-2019)
• 11.7 Other Revenue Growth (2014-2019)

12 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Forecast (2019-2024)

• 12.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Forecast (2019-2024)
• 12.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Forecast by Regions (2019-2024)
• 12.3 North America Gene Modifying Immunotherapy for Blood Cancer Revenue Market Forecast (2019-2024)
• 12.4 Europe Gene Modifying Immunotherapy for Blood Cancer Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific Gene Modifying Immunotherapy for Blood Cancer Revenue Market Forecast (2019-2024)
• 12.6 South America Gene Modifying Immunotherapy for Blood Cancer Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa Gene Modifying Immunotherapy for Blood Cancer Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology